---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-24-000117"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2024-10-29T23:59:59+00:00"
generated_at: "2026-05-30T08:58:20.486546+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kiora receives IND approval for Phase 2 trial of KIO-301 in retinitis pigmentosa

## Summary
- ABACUS-2 is a 36-patient, multi-center, double-masked, randomized, controlled Phase 2 trial.
- Enrolling patients with ultra-low vision or no light perception regardless of gene mutation.
- First patient dosing expected next year after validation of novel functional vision endpoints.
- KIO-301 is a light-sensitive small molecule photoswitch targeting retinal ganglion cells.
- Primary endpoints include safety, tolerability; key efficacy: functional vision and visual acuity tests.

## SEC filing metadata
- accession: 0001372514-24-000117
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2024-10-29T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251424000117/0001372514-24-000117-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251424000117/kprx-20241029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-24-000117
- JSON: https://secwatch.observer/filing/0001372514-24-000117.json
- Plain text: https://secwatch.observer/filing/0001372514-24-000117.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.